Trial · NCT01559363
Adverse event totals18
The totals the trial posted for each group.
1 to 18 of 18
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing | 0 | 24 |
| Total, all-cause mortality | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | 0 | 8 |
| Total, all-cause mortality | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | 0 | 5 |
| Total, all-cause mortality | Phase 2a: Cohort 4: Tesevatinib: Bi-weekly Dosing | 0 | 10 |
| Total, all-cause mortality | Phase 2a: Cohort 5: Tesevatinib: Tri-weekly Dosing | 0 | 14 |
| Total, all-cause mortality | Phase 2a: SILK Cohort: Tesevatinib 50 mg Once Daily Dosing | 0 | 8 |
| Total, other adverse events | Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing | 24 | 24 |
| Total, other adverse events | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | 8 | 8 |
| Total, other adverse events | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | 5 | 5 |
| Total, other adverse events | Phase 2a: Cohort 4: Tesevatinib: Bi-weekly Dosing | 10 | 10 |
| Total, other adverse events | Phase 2a: Cohort 5: Tesevatinib: Tri-weekly Dosing | 14 | 14 |
| Total, other adverse events | Phase 2a: SILK Cohort: Tesevatinib 50 mg Once Daily Dosing | 8 | 8 |
| Total, serious adverse events | Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing | 1 | 24 |
| Total, serious adverse events | Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing | 0 | 8 |
| Total, serious adverse events | Phase 1b: Cohort 3: Tesevatinib 150 mg Once Daily Dosing | 0 | 5 |
| Total, serious adverse events | Phase 2a: Cohort 4: Tesevatinib: Bi-weekly Dosing | 1 | 10 |
| Total, serious adverse events | Phase 2a: Cohort 5: Tesevatinib: Tri-weekly Dosing | 0 | 14 |
| Total, serious adverse events | Phase 2a: SILK Cohort: Tesevatinib 50 mg Once Daily Dosing | 1 | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01559363/event-totals